Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Granisetron

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    20 result(s) found for: Granisetron. Displaying page 1 of 1.
    EudraCT Number: 2005-006042-41 Sponsor Protocol Number: NC3-project Start Date*: 2006-05-15
    Sponsor Name:Karolinska Institutet
    Full Title: Local treatment of craniomandibular myofascial pain with the 5-HT3 receptor antagonist granisetron. A randomized and double-blind study.
    Medical condition: Craniomandibular myalgia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003260-39 Sponsor Protocol Number: ML16633 Start Date*: 2016-08-05
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: Intravenous Granisetron (Kytril) in the Prevention of Post-Operative Nausea and Vomiting (PONV) in Pediatric Subjects Undergoing Tonsillectomy or Adenotonsillectomy
    Medical condition: Prevention of Post-operative Nausea and Vomiting (PONV) in pediatric subjects
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10036901 Prophylaxis against postoperative nausea and vomiting LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-006206-27 Sponsor Protocol Number: Gra-geneticver1 Start Date*: 2012-02-21
    Sponsor Name:Karolinska Institutet
    Full Title: Does 5-HT polymorphism contribute to pain regulation and efficacy of granisetron?
    Medical condition: Experimentally induced muscle pain in healthy volunteers, both sexes and over 18 years of age.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000026-57 Sponsor Protocol Number: Gra-sensv1 Start Date*: 2013-07-19
    Sponsor Name:Karolinska Institutet
    Full Title: Effect of granisetron on facial skin sensitivity in healthy volunteers
    Medical condition: Healthy and pain-free volunteers > 20 years of age, both sexes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2005-005003-41 Sponsor Protocol Number: 392MD/15/C Start Date*: Information not available in EudraCT
    Sponsor Name:Strakan Pharmaceuticals Ltd
    Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004642-41 Sponsor Protocol Number: NICHD-2011-POPS Start Date*: 2015-04-10
    Sponsor Name:University Hospital Southampton NHS Foundation Trust
    Full Title: Pharmacokinetics of Understudied Drugs Administered to Children per Standard of Care
    Medical condition:
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Not Authorised)
    Trial results: (No results available)
    EudraCT Number: 2007-005068-29 Sponsor Protocol Number: C2006-01 Start Date*: Information not available in EudraCT
    Sponsor Name:A.P. Pharma, Inc.
    Full Title: A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi® for the Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea a...
    Medical condition: Chemotherapy Induced Nausea and Vomiting
    Disease: Version SOC Term Classification Code Term Level
    9.1 10054133 Prophylaxis of nausea and vomiting LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-020509-34 Sponsor Protocol Number: RBHP 2010 DUBRAY Start Date*: 2010-07-13
    Sponsor Name:CHU de Clermont-Ferrand
    Full Title: Etude comparative de l'influence de deux antagonistes du récepteur 5-HT3, le tropisétron et le granisétron, sur l'effet analgésique du paracétamol.
    Medical condition: INTERACTION ENTRE LE TROPISETRON, LE GRANISETRON ET LE PARACETAMOL
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-003669-32 Sponsor Protocol Number: GONO-Sancuso Start Date*: 2020-07-03
    Sponsor Name:G.O.N.O. - GRUPPO ONCOLOGICO DEL NORD OVEST
    Full Title: GRANISETRON TRANSDERMAL SYSTEM (GTDS) IN PREVENTING NAUSEA AND VOMITING INDUCED BY CISPLATIN-BASED CHEMOTHERAPY AND CONCURRENT RADIOTHERAPY FOR HEAD AND NECK CANCER
    Medical condition: Head and neck cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004855 10046311 Upper respiratory tract neoplasms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022746-24 Sponsor Protocol Number: TS-P04834 Start Date*: 2012-05-07
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy- Induced Nausea and Vomiting (CINV) in Subject...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Moderately Emetogenic Chemotherapy (MEC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) LV (Completed) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) BG (Completed) SK (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-022743-37 Sponsor Protocol Number: TS-P04833 Start Date*: 2012-09-14
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects ...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    14.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) CZ (Completed) PL (Completed) SK (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-000405-27 Sponsor Protocol Number: 05JM128 Start Date*: 2006-06-01
    Sponsor Name:Greenpark Health Care Trust
    Full Title: Postoperative pain and mobility outcomes after primary hip and knee arthroplasty. A comparison of intravenous morphine with local wound infiltration.
    Medical condition: Osteoarthritis of the hip and knee joints
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2004-004956-38 Sponsor Protocol Number: EmNa Start Date*: 2005-06-06
    Sponsor Name:Gerlinde Egerer (MD); Internal Medicine, Department V
    Full Title: Randomised, placebo controlled, single-center, double-blind clinical trial to investigate efficacy and safety of Aprepitant combined with Kevatril and Dexamethasone versus Placebo combined with Kev...
    Medical condition: multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022742-25 Sponsor Protocol Number: TS-P04832 Start Date*: 2012-04-16
    Sponsor Name:Tesaro, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Active-Controlled Study of the Safety and Efficacy of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects ...
    Medical condition: Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10049091 Chemotherapy antiemetic prophylaxis LLT
    14.1 10042613 - Surgical and medical procedures 10054133 Prophylaxis of nausea and vomiting PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BE (Completed) PT (Completed) BG (Completed) ES (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018665-30 Sponsor Protocol Number: KKSH-079 Start Date*: 2010-06-30
    Sponsor Name:Martin-Luther University Halle-Wittenberg
    Full Title: COMFORT-study Comparison of Olanzapin and Metoclopramide For treatment Of bReakThrough emesis
    Medical condition: Patienten, die trotz maximaler Standardantiemese mit Granisetron, Dexamethason und Aprepitant unter chemotherapie-induzierter Übelkeit und Erbrechen leiden.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028813 Nausea LLT
    12.1 10014542 Emesis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000755-18 Sponsor Protocol Number: AMENO2 Start Date*: 2006-06-26
    Sponsor Name:Fundación PETHEMA
    Full Title: Estudio Fase IV, Nacional, Multicéntrico, competitivo, aleatorizado, doble ciego, controlado de grupos paralelos, para determinar la seguridad, tolerabilidad, y eficacia de aprepitant, más palonose...
    Medical condition: náuseas y vómitos producidos en pacientes tratados con quimioterapia previa al transplante de progenitores hematopoyéticos
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002944-25 Sponsor Protocol Number: EuroHyp-1 Start Date*: 2014-08-20
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: EuroHYP-1: European multicentre, randomised, phase III clinical trial of therapeutic hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke
    Medical condition: Acute ischaemic stroke
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) IT (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-004686-41 Sponsor Protocol Number: IBA1160 Start Date*: 2020-12-02
    Sponsor Name:Helsinn Healthcare SA
    Full Title: MyRisk: Efficacy and safety evaluation of oral Akynzeo® in patients receiving MEC at high risk of developing CINV based on a prediction tool. A multinational and multicenter study.
    Medical condition: Patients treated with IV moderately emetogenic chemotherapy and at high risk of chemotherapy induced nausea and vomiting (CINV)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) CZ (Completed) DE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-001833-87 Sponsor Protocol Number: 00600 Start Date*: 2008-06-20
    Sponsor Name:University Medical Center Freiburg
    Full Title: Use of Palifermin to reduce the duration, frequency and severity of oral mucositis after high dose therapy with BEAM and autologous peripheral blood stem cell transplantation in patients with malig...
    Medical condition: malign lymphoma (primary high risks patients: - therapy refractory / relapsed NHL - therapy refractory / relapsed M. Hodgkin - Burkitt-NHL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006595 Burkitt's lymphoma LLT
    9.1 10029609 Non-Hodgkin's lymphoma unspecified histology aggressive recurrent LLT
    9.1 10029610 Non-Hodgkin's lymphoma unspecified histology aggressive refractory LLT
    9.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002340-24 Sponsor Protocol Number: 0517-029 Start Date*: 2012-10-26
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for...
    Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10042613 - Surgical and medical procedures 10036899 Prophylaxis against chemotherapy induced vomiting LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) PT (Completed) DE (Completed) AT (Completed) HU (Completed) EE (Completed) GB (Completed) LT (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 07 17:07:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA